Abstract
Objective: To review recent epidemiologic studies of vaccination and melanoma risk as well as critically discuss the different melanoma vaccines under investigation in multicenter phase III melanoma vaccine trials. Data Sources: A retrospective review of the literature. Study Selection: Studies included those on the risk of melanoma and vaccination, historically relevant data, and ongoing or recently published phase III melanoma vaccine trials. The referenced study designs and methodologies varied. Data extraction and Synthesis: 3 reviewers extracted Data and the main results are presented in a quantitative descriptive manner. Conclusion: Vaccine therapy of melanoma remains promising, given the associated low toxicity. Epidemiologic studies suggest a role for vaccines against certain infectious diseases in melanoma prevention. While results of ongoing phase III melanoma vaccines trials may open new avenues for disease prevention, a better understanding of immune responses to melanoma vaccines will be necessary.
Keywords: immunosuppression, bacille calmette-guerin (bcg), fibrosarcoma, t-lymphocytes, melanoma vaccines, immune system, adjuvant chemotherapy, delayed-type hypersensitivity (dth), viral oncolysates
Current Cancer Therapy Reviews
Title: Vaccine Therapy of Melanoma: An Update
Volume: 1 Issue: 2
Author(s): Marie-France Demierre, Susan M. Swetter and Vernon K. Sondak
Affiliation:
Keywords: immunosuppression, bacille calmette-guerin (bcg), fibrosarcoma, t-lymphocytes, melanoma vaccines, immune system, adjuvant chemotherapy, delayed-type hypersensitivity (dth), viral oncolysates
Abstract: Objective: To review recent epidemiologic studies of vaccination and melanoma risk as well as critically discuss the different melanoma vaccines under investigation in multicenter phase III melanoma vaccine trials. Data Sources: A retrospective review of the literature. Study Selection: Studies included those on the risk of melanoma and vaccination, historically relevant data, and ongoing or recently published phase III melanoma vaccine trials. The referenced study designs and methodologies varied. Data extraction and Synthesis: 3 reviewers extracted Data and the main results are presented in a quantitative descriptive manner. Conclusion: Vaccine therapy of melanoma remains promising, given the associated low toxicity. Epidemiologic studies suggest a role for vaccines against certain infectious diseases in melanoma prevention. While results of ongoing phase III melanoma vaccines trials may open new avenues for disease prevention, a better understanding of immune responses to melanoma vaccines will be necessary.
Export Options
About this article
Cite this article as:
Demierre Marie-France, Swetter M. Susan and Sondak K. Vernon, Vaccine Therapy of Melanoma: An Update, Current Cancer Therapy Reviews 2005; 1 (2) . https://dx.doi.org/10.2174/1573394054021718
DOI https://dx.doi.org/10.2174/1573394054021718 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Repair and Translesion DNA Polymerases as Anticancer Drug Targets
Anti-Cancer Agents in Medicinal Chemistry The Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma Multiforme and other Malignant Neoplasms
Anti-Cancer Agents in Medicinal Chemistry Group-sparse Modeling Drug-kinase Networks for Predicting Combinatorial Drug Sensitivity in Cancer Cells
Current Bioinformatics New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Synthesis, Characterization and Evaluation of 1,3-Bisindolyl-2-Propen-1- One Derivatives as Potent Anti-Breast Cancer Agents
Current Bioactive Compounds Anti-cancer Potential of Phyto-alkaloids: A Prospective Review
Current Cancer Therapy Reviews Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine The Pursuit of Differentiated Ligands for the Glucocorticoid Receptor
Current Topics in Medicinal Chemistry Bioinorganic Chemistry: The Study of the Fate of Platinum-Based Antitumour Drugs
Current Chemical Biology Heparanase Inhibitors Facilitate the Assembly of the Basement Membrane in Artificial Skin
Current Tissue Engineering (Discontinued) Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Artesunate Enhances the Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets A Potent Inhibitor of Steroid Sulfatase (EM-1913) Blocks Tumor Growth in Nude Mice (MCF-7 Xenograft)
Current Enzyme Inhibition Transient Receptor Potential (TRP) Channels and Cardiac Fibrosis
Current Topics in Medicinal Chemistry Colon Cancer Therapy: Recent Developments in Nanomedicine to Improve the Efficacy of Conventional Chemotherapeutic Drugs
Anti-Cancer Agents in Medicinal Chemistry Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer
Mini-Reviews in Medicinal Chemistry Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets Thalidomide in Multiple Myeloma
Current Pharmaceutical Biotechnology